

Senate
File
572
-
Introduced


SENATE
FILE
572


BY
COMMITTEE
ON
STATE


GOVERNMENT


(SUCCESSOR
TO
SSB
1230)


A
BILL
FOR


An
Act
relating
to
controlled
substances,
including
amending
1


information
collection
and
reporting
requirements
under
2


the
Iowa
prescription
monitoring
program,
amending
the
3


controlled
substance
schedules,
removing
certain
references
4


to
marijuana,
making
penalties
applicable,
and
including
5


effective
date
provisions.
6


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
7


TLSB
1186SV
(1)
88


ss/rh



S.F.
572


DIVISION
I
1


IOWA
PRESCRIPTION
MONITORING
PROGRAM
INFORMATION
2


Section
1.
Section
124.554,
subsection
1,
paragraph
g,
Code
3


2019,
is
amended
to
read
as
follows:
4


g.
Including
all
schedule
schedules
II
,
III,
and
IV
5


controlled
substances,
those
substances
in
schedules
III
and
IV


6


that
the
advisory
council
and
board
determine
can
be
addictive
7


or
fatal
if
not
taken
under
the
proper
care
and
direction
8


of
a
prescribing
practitioner,
and


schedule
V
controlled
9


substances
including
when
dispensed
by
a
pharmacist
without
10


a
prescription,
except
for
sales
of
pseudoephedrine
which


11


are
reported
to
the
real-time
electronic
repository,
opioid
12


antagonists
,
and
other
prescription
substances
that
the
board
13


and
advisory
council
determine
can
be
addictive
or
fatal
if


14


not
taken
under
the
proper
care
and
direction
of
a
prescribing
15


practitioner
.
16


Sec.
2.
Section
124.554,
subsection
2,
unnumbered
paragraph
17


1,
Code
2019,
is
amended
to
read
as
follows:
18


Beginning
January


February
1,
2007
2020
,
and
annually
by
19


January
February
1
thereafter,
the
board
and
advisory
council
20


shall
present
to
the
general
assembly
and
the
governor
a
21


report
prepared
consistent
with
section
124.555,
subsection
3
,
22


paragraph
“d”
,
which
shall
include
but
not
be
limited
to
the
23


following:
24


DIVISION
II
25


CONTROLLED
SUBSTANCE
SCHEDULES
26


Sec.
3.
Section
124.204,
subsection
2,
Code
2019,
is
amended


27


by
adding
the
following
new
paragraph:
28


NEW
PARAGRAPH


.
be.
MT-45
(1-cyclohexyl-4-(1,2-
29


diphenylethyl)piperazine).
30


Sec.
4.
Section
124.204,
subsection
4,
paragraph
m,
Code
31


2019,
is
amended
to
read
as
follows:
32


m.
Marijuana
,
except
as
otherwise
provided
by
rules
of
the


33


board
for
medicinal
purposes


.
34


Sec.
5.
Section
124.204,
subsection
4,
paragraph
u,
35


-1-


LSB
1186SV
(1)
88


ss/rh
1/
5



























S.F.
572


unnumbered
paragraph
1,
Code
2019,
is
amended
to
read
as
1


follows:
2


Tetrahydrocannabinols,
except
as
otherwise
provided


3


by
rules
of
the
board
for
medicinal
purposes,
meaning
4


tetrahydrocannabinols
naturally
contained
in
a
plant
of
5


the
genus
Cannabis
(Cannabis
plant)
as
well
as
synthetic
6


equivalents
of
the
substances
contained
in
the
Cannabis
plant,
7


or
in
the
resinous
extractives
of
such
plant,
and
synthetic
8


substances,
derivatives,
and
their
isomers
with
similar
9


chemical
structure
and
pharmacological
activity
to
those
10


substances
contained
in
the
plant,
such
as
the
following:
11


Sec.
6.
Section
124.204,
subsection
6,
paragraph
i,
Code
12


2019,
is
amended
by
adding
the
following
new
subparagraph:
13


NEW
SUBPARAGRAPH


.
(27)
1-(1,3-benzodioxol-5-yl)-2-
14


(ethylamino)-pentan-1-one.
Other
names:
N-ethylpentylone
or
15


ephylone.
16


Sec.
7.
Section
124.204,
subsection
7,
Code
2019,
is
amended
17


by
striking
the
subsection.
18


Sec.
8.
Section
124.204,
subsection
9,
Code
2019,
is
amended
19


by
adding
the
following
new
paragraphs:
20


NEW
PARAGRAPH


.
af.
N-(1-phenethylpiperidin-4-yl)-N-
21


phenylcyclopropanecarboxamide,
its
isomers,
esters,
ethers,
22


salts
and
salts
of
isomers,
esters,
and
ethers.
Other
name:
23


cyclopropyl
fentanyl.
24


NEW
PARAGRAPH


.
ag.
N-(1-phenethylpiperidin-4-yl)-N-
25


phenylpentanamide,
its
isomers,
esters,
ethers,
salts
and
salts
26


of
isomers,
esters
and
ethers.
Other
name:
valeryl
fentanyl.
27


NEW
PARAGRAPH
.
ah.
N-(4-fluorophenyl)-N-(1-
28


phenethylpiperidin-4-yl)butyramide,
its
isomers,
esters,
29


ethers,
salts
and
salts
of
isomers,
esters,
and
ethers.
Other


30


name:
para-fluorobutyryl
fentanyl.
31


NEW
PARAGRAPH


.
ai.
N-(4-methoxyphenyl)-N-
32


(1-phenethylpiperidin-4-yl)butryamide,
its
isomers,
esters,
33


ethers,
salts
and
salts
of
isomers,
esters,
and
ethers.
Other


34


name:
para-methyoxybutyryl
fentanyl.
35


-2-


LSB
1186SV
(1)
88


ss/rh
2/
5










S.F.
572


NEW
PARAGRAPH
.
aj.
N-(4-chlorophenyl)-N-(1-
1


phenethylpiperidin-4-yl)isobutryramide,
its
isomers,
esters,
2


ethers,
salts
and
salts
of
isomers,
esters,
and
ethers.
Other
3


name:
para-chloroisobutyryl
fentanyl.
4


NEW
PARAGRAPH
.
ak.
N-(1-phenethylpiperidin-4-yl)-
5


N-phenylisobutyramide,
its
isomers,
esters,
ethers,
salts
and
6


salts
of
isomers,
esters,
and
ethers.
Other
name:
isobutyryl
7


fentanyl.
8


NEW
PARAGRAPH


.
al.
N-(1-phenethylpiperidin-4-yl)-
9


N-phenylcyclopentanecarboxamide,
its
isomers,
esters,
ethers,
10


salts
and
salts
of
isomers,
esters,
and
ethers.
Other
name:
11


cyclopentyl
fentanyl.
12


NEW
PARAGRAPH


.
am.
N-(2-fluorophenyl)-2-methoxy-N-
13


(1-phenethylpiperidin-4-yl)acetamide,
its
isomers,
esters,
14


ethers,
salts
and
salts
of
isomers,
esters,
and
ethers.
Other
15


name:
ocfentanil.
16


NEW
PARAGRAPH


.
an.
Fentanyl-related
substances,
their
17


isomers,
esters,
ethers,
salts
and
salts
of
isomers,
esters
18


and
ethers.
“Fentanyl-related
substance”
means
any
substance
19


not
otherwise
listed
under
this
schedule
or
another
schedule,
20


and
for
which
no
exemption
or
approval
is
in
effect
under
21


section
505
of
the
federal
Food,
Drug,
and
Cosmetic
Act
that
22


is
structurally
related
to
fentanyl
by
one
or
more
of
the
23


following
modifications:
24


(1)
Replacement
of
the
phenyl
portion
of
the
phenethyl
group
25


by
any
monocycle,
whether
or
not
further
substituted
in
or
on
26


the
monocycle.
27


(2)
Substitution
in
or
on
the
phenethyl
group
with
alkyl,
28


alkenyl,
alkoxyl,
hydroxyl,
halo,
haloalkyl,
amino,
or
nitro
29


groups.
30


(3)
Substitution
in
or
on
the
piperidine
ring
with
alkyl,
31


alkenyl,
alkoxyl,
ester,
ether,
hydroxyl,
halo,
haloalkyl,
32


amino,
or
nitro
groups.
33


(4)
Replacement
of
the
aniline
ring
with
any
aromatic
34


monocycle
whether
or
not
further
substituted
in
or
on
the
35


-3-


LSB
1186SV
(1)
88


ss/rh
3/
5








S.F.
572


aromatic
monocycle.
1


(5)
Replacement
of
the
N
-propionyl
group
by
another
acyl
2


group.
3


NEW
PARAGRAPH


.
ao.
Naphthalen-1-yl
1-(5-fluoropentyl)-
4


1
H
-indole-3-carboxylate.
Other
names:
NM2201
or
CBL2201.
5


NEW
PARAGRAPH
.
ap.
N
-(1-amino-3-methyl-1-oxobutan-
6


2-yl)-1-(5-fluoropentyl)-1
H
-indazole-3-carboxamide.
Other
7


name:
5F-AB-PINACA.
8


NEW
PARAGRAPH


.
aq.
1-(4-cyanobutyl)-
N
-(2-phenylpropan-
9


2-yl)-1
H
-indazole-3-carboxamide.
Other
names:
10


4-CN-CUMYL-BUTINACA,
4-cyano-CUMYL-BUTINACA,
4-CN-CUMYL
11


BINACA,
CUMYL-4CN-BINACA,
or
SGT-78.
12


NEW
PARAGRAPH


.
ar.
Methyl
2-(1-(cyclohexylmethyl)-1
H
-
13


indole-3-carboxamido)-3-methylbutanoate.
Other
names:
14


MMB-CHMICA
or
AMB-CHMICA.
15


NEW
PARAGRAPH


.
as.
1-(5-fluoropentyl)-
N
-(2-
16


phenylpropan-2-yl)-1
H
-pyrrolo[2,3-b]pyridine-3-carboxamide.
17


Other
name:
5F-CUMYL-P7AICA.
18


Sec.
9.
Section
124.206,
subsection
7,
paragraph
a,
Code
19


2019,
is
amended
by
striking
the
paragraph.
20


Sec.
10.
Section
124.208,
subsection
3,
paragraph
c,
Code
21


2019,
is
amended
to
read
as
follows:
22


c.
Any
substance
which
contains
any
quantity
of
a
derivative
23


of
barbituric
acid
or
any
salt
thereof
including
but
not


24


limited
to
Fioricet
.
25


Sec.
11.
Section
124.212,
Code
2019,
is
amended
by
adding
26


the
following
new
subsection:
27


NEW
SUBSECTION
.
6.
Approved
cannabidiol
drugs.
A
drug
28


product
in
finished
dosage
formulation
that
29


has
been
approved
by
the
United
States
food
and
30


drug
administration
that
contains
cannabidiol
31


(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
32


pentyl-1,3-benzenediol)
derived
from
cannabis
and
no
more
than
33


0.1
percent
(w/w)
residual
tetrahydrocannabinols.
34


Sec.
12.
EFFECTIVE
DATE.
This
division
of
this
Act,
being
35


-4-


LSB
1186SV
(1)
88


ss/rh
4/
5











S.F.
572


deemed
of
immediate
importance,
takes
effect
upon
enactment.
1


EXPLANATION
2


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
3


the
explanation’s
substance
by
the
members
of
the
general
assembly.
4


DIVISION
I
——
IOWA
PRESCRIPTION
MONITORING
PROGRAM
5


INFORMATION
REPORTING.
This
division
expands
reporting
to
6


the
Iowa
prescription
monitoring
program
(PMP)
to
include
7


those
controlled
substances
in
schedules
III,
IV,
and
V
8


under
the
Iowa
uniform
controlled
substances
Act
(Act)
9


which
are
dispensed
to
patients
in
Iowa.
This
bill
requires
10


all
dispensations
of
schedules
III,
IV,
and
V
controlled
11


substances,
including
those
that
do
not
require
a
prescription
12


to
be
dispensed
by
a
pharmacist,
to
be
reported
to
the
PMP,
13


except
for
dispensations
of
pseudoephedrine,
which
are
reported
14


to
the
real-time
electronic
repository.
The
division
also
15


extends
the
reporting
requirement
to
other
prescription
16


substances
that
the
board
of
pharmacy
and
the
PMP
advisory
17


council
determine
could
be
addictive
or
fatal
if
not
taken
18


under
the
care
and
direction
of
a
prescribing
practitioner.
19


The
division
also
changes
the
due
date
for
annual
reports
to
20


the
governor
and
legislature
regarding
the
PMP
from
January
1
21


to
February
1.
22


DIVISION
II
——
CONTROLLED
SUBSTANCE
SCHEDULES.
This
23


division
adds
one
opioid
analgesic,
one
synthetic
cathinone,
24


five
synthetic
cannabinoids,
and
nine
synthetic
opioids
25


to
schedule
I
of
the
Act,
and
any
FDA-approved
products
26


containing
cannabidiol
that
contain
no
more
than
0.1
percent
27


tetrahydrocannabinols
to
schedule
V
of
the
Act.
28


The
division
designates
all
products
which
contain
29


derivatives
of
barbituric
acid
(butalbital)
as
schedule
III
30


controlled
substances
under
the
Act,
subject
to
reporting
to
31


the
PMP.


32


The
division
strikes
language
referring
to
medical
marijuana
33


programs
of
the
board
of
pharmacy.
34


The
division
becomes
effective
upon
enactment.
35


-5-


LSB
1186SV
(1)
88


ss/rh
5/
5

